BCL10 antibody (B-Cell CLL/lymphoma 10)

Details for Product anti-BCL10 Antibody No. ABIN965650, Supplier: Log in to see
Antigen
  • CARMEN
  • CIPER
  • CLAP
  • c-E10
  • mE10
  • BCL10
  • AI132454
  • BCL-10
  • C81403
  • ME10
  • cE10
  • bcl10
  • B-cell CLL/lymphoma 10
  • B cell leukemia/lymphoma 10
  • B-cell lymphoma/leukemia 10
  • BCL10
  • Bcl10
  • bcl10
  • LOC100223183
Alternatives
anti-Human BCL10 antibody for Western Blotting
Reactivity
Human
300
94
48
2
2
1
1
1
1
1
1
1
Host
175
123
4
Clonality
Monoclonal
Conjugate
This BCL10 antibody is un-conjugated
11
10
10
8
6
5
4
4
4
4
4
4
4
4
4
4
4
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
Application
Immunohistochemistry (IHC), ELISA, Western Blotting (WB)
232
137
115
109
97
88
60
33
26
13
3
3
2
2
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Isotype IgG1
Specificity Ni-NTA purified recombinant human BCL-10 expressed in E. Coli strain BL21 (DE3).
Purification Antibodies are purified by protein A affinity chromatography
Alternative Name BCL-10 (BCL10 Antibody Abstract)
Background Bcl-10 is a 31kDa protein containing a caspase recruitment domain (CARD). It plays an important role in apoptosis and activating NF-kappaB. The research suggested that it interacted with other CARD domain containing proteins including CARD9, 10, 11 and 14, which were thought to function as upstream regulators in NF-kappaB signaling. Bcl10 is found to form a complex with MALT1 which encoded by another gene known to be translocated in MALT lymphoma. MALT1 and Bcl-10 are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy.
Gene ID 8915
Pathways TCR Signaling, Fc-epsilon Receptor Signaling Pathway, Activation of Innate immune Response, Positive Regulation of Immune Effector Process, Production of Molecular Mediator of Immune Response, Tube Formation, Positive Regulation of Endopeptidase Activity
Application Notes IHC(P): Dilution 1: 100- 1: 500
IHC(F): Dilution 1: 200- 1: 1000
Western blot: Dilution 1: 2000- 1: 5000
ELISA: Propose dilution 1: 10000.
Determining optimal working dilutions by titration test.
Restrictions For Research Use only
Storage -20 °C
Background publications Lucas, Yonezumi, Inohara, McAllister-Lucas, Abazeed, Chen, Yamaoka, Seto, Nunez: "Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway." in: The Journal of biological chemistry, Vol. 276, Issue 22, pp. 19012-9, 2001 (PubMed).

Wang, Guo, Huang, Ke, Poyet, Manji, Merriam, Glucksmann, DiStefano, Alnemri, Bertin: "Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B." in: The Journal of biological chemistry, Vol. 276, Issue 24, pp. 21405-9, 2001 (PubMed).

Hinoi, Tani, Lucas, Caca, Dunn, Macri, Loda, Appelman, Cho, Fearon: "Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon." in: The American journal of pathology, Vol. 159, Issue 6, pp. 2239-48, 2001 (PubMed).

Schillace, Voltz, Sim, Shenolikar, Scott: "Multiple interactions within the AKAP220 signaling complex contribute to protein phosphatase 1 regulation." in: The Journal of biological chemistry, Vol. 276, Issue 15, pp. 12128-34, 2001 (PubMed).

Willis, Jadayel, Du, Peng, Perry, Abdul-Rauf, Price, Karran, Majekodunmi, Wlodarska, Pan, Crook, Hamoudi, Isaacson, Dyer: "Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types." in: Cell, Vol. 96, Issue 1, pp. 35-45, 1999 (PubMed).

Rudd: "Adaptors and molecular scaffolds in immune cell signaling." in: Cell, Vol. 96, Issue 1, pp. 5-8, 1999 (PubMed).

Product cited in: Cahill: "Vasoconstrictor responsiveness of portal hypertensive vessels." in: Clinical science (London, England : 1979), Vol. 96, Issue 1, pp. 3-4, 1999 (PubMed).

Did you look for something else?